LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.

The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.

Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.